NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (OTCQB:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will commence trading its common shares on the NYSE MKT beginning on March 26, 2014.
Help employers find you! Check out all the jobs and post your resume.
